Treatment with Sequential Intravenous or Oral Moxifloxacin Was Associated with Faster Clinical Improvement than Was Standard Therapy for Hospitalized Patients with Community-Acquired Pneumonia Who Received Initial Parenteral Therapy
Clicks: 140
ID: 267384
2005
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
140 views
14 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #526 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background. Although third-generation cephalosporins, such as ceftriaxone (CTRX), and pneumococcal fluoroquinolones, such as moxifloxacin (MXF), are currently r
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (18 words).
Try re-searching for a better abstract.
| Reference Key |
tobias2005clinicaltreatment
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Welte, Tobias;Petermann, Wolfgang;Schürmann, Dirk;Thomas Bauer, Torsten;Reimnitz, Peter;Study Group Moxirapid; |
| Journal | clinical infectious diseases |
| Year | 2005 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.